Veradermics Drops 13% Despite Phase 3 Trial Wins
Veradermics (MANE) dropped 13.3% following positive Phase 3 trial results for VDPHL01, an oral treatment for androgenetic alopecia. However, company insiders had sold $92.41 million in stock in the 90
Veradermics Shares Drop 13% Despite Phase 3 Wins
NEW YORK, November 13 —
Veradermics, Incorporated (MANE) dropped 13.3% as investors processed what the company described as positive Phase 3 trial data alongside a Q3 net loss that beat consensus estimates by 19.5%. For a pre-revenue biotech whose $5.71 billion market cap rests entirely on its clinical pipeline, a sell-off on Phase 3 progress demands an explanation.
- Q3 net loss $21.0M, widened from $20.1M year-over-year; EPS of -$0.50 beat consensus by 19.5% per the Q3 8-K
- Cash of $798.4M projected to fund operations into 2030; free cash flow -$55M TTM, zero debt
- Net insider activity: $92.41M in sales, zero purchases, over 90 days per SEC filings
The Momentum Run Preceded the Data
Coverage from three days before November 13 noted MANE was climbing, meaning the decline followed a near-term run-up rather than arriving as cold news. Veradermics is developing VDPHL01, an oral non-hormonal treatment for androgenetic alopecia targeting both men and women, the company's most advanced clinical asset, with Phase 3 trials 302 and 304 described as positive. With zero product revenue and a 0.0% gross margin, the clinical readout carries the full weight of the valuation. A Regulation FD 8-K filed November 9, one day before earnings, suggests investors may have been responding to that accompanying disclosure, not the trial data alone.
Insiders Booked $92 Million Before the Phase 3 Win
Per SEC filings, Montanova Capital LLC sold 750,000 shares at $107.25 on August 19; CEO Reid Waldman sold 67,500 shares at prices between $106.72 and $111.28 on August 17; CTO Timothy Durso sold 43,500 shares the same date. The combined 90-day tally was $92.41 million in sales against zero purchases from any reporting insider. All three exited at prices below the current $135.29, suggesting the sales represented pre-readout risk reduction rather than a view on the final data outcome. The absence of any offsetting buying ahead of data the company describes as positive is the asymmetric signal investors are still parsing.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| MANE | $5.7B | n/a | +314.7% |
| ORKA | $7.1B | n/a | +306.3% |
| SYRE | $9.8B | n/a | +372.0% |
| ABSI | $1.6B | n/a | +283.3% |
| KLRA | $1.7B | n/a | -44.7% |
| COAG | $1.8B | n/a | +15.7% |
Full Data Package Sets the Next Threshold
With $798.4 million in cash projected to fund operations into 2030, Veradermics carries runway but not revenue. At $135.29, the stock offers 38% upside to the consensus analyst target of $187.33 despite two consecutive EPS beats; short interest at 12.3% of float means a confirmed NDA filing could force covering. The next disclosure that settles the sell-off question is the full Phase 3 data package and any FDA meeting timeline. Any discounted cash flow analysis for MANE starts with assumed peak VDPHL01 sales, not trailing revenue. Run the free Veradermics, Incorporated deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why did Veradermics stock drop despite Phase 3 wins?
Veradermics (MANE) dropped 13.3% following positive Phase 3 trial results because the stock had already run up in the three days before the announcement. More significantly, company insiders had sold $92.41 million in stock over the previous 90 days with no offsetting purchases, signaling doubt despite the positive data.
Which Veradermics executives sold stock before Phase 3?
CEO Reid Waldman sold 67,500 shares between $106.72 and $111.28 on August 17, and CTO Timothy Durso sold 43,500 shares the same date. Additionally, Montanova Capital LLC sold 750,000 shares at $107.25 on August 19, all well before the Phase 3 announcement.
What is VDPHL01 used for?
VDPHL01 is an oral non-hormonal treatment for androgenetic alopecia (hair loss) targeting both men and women. It is Veradermics' most advanced clinical asset, with Phase 3 trials 302 and 304 described as positive.
How long is Veradermics funded?
With $798.4 million in cash, Veradermics is projected to fund operations into 2030. The company has zero debt and carries zero product revenue, meaning the valuation depends entirely on successful clinical development of VDPHL01.
What is the Veradermics stock price target?
Analysts have set a consensus price target of $187.33, representing 38% upside from $135.29. With short interest at 12.3% of float, a confirmed NDA filing could force covering among short sellers.
Veradermics stock fell 13.3% as investors digested what the company described as positive Phase 3 trial data alongside a Q3 net loss that widened year-over-year yet beat consensus estimates by 19.5%. For a pre-revenue biotech whose entire value rests on its clinical pipeline, a sell-the-news reaction to its most important milestones is the question the article exists to answer.